You are here: Home » Companies » News
Business Standard

US FDA revokes approval to Sun Pharma's anti epilepsy drug

US FDA had made adverse observations in their audit of Halol plant last year

BS Reporter  |  Mumbai 

A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai

US Food and Drugs Administration has withdrawn an approval granted in March to Sun Pharma Advanced Research Company’s (SPARC) anti-epileptic drug due to regulatory compliance issues at Sun Pharma's Halol plant.

SPARC, which earlier in the week filed letter of offer with Sebi to raise Rs 250 crore through rights issue, had received FDA approval for its Elepsia XR tablets (Levetiracetam) in March.

Analysts estimated modest sales of about $50 million annually from Elepsia XR which is to be manufactured at Sun Pharma's Halol plant.

“SPARC had earlier received a final approval from USFDA in March 2015 for this product and was evaluating several marketing partners for commercialisation. However SPARC has now received a complete response letter from the USFDA rescinding its earlier approval, citing that the compliance status of the manufacturing facility was not acceptable on the date of approval,” company said in a statement. It added that Sun Pharmaceuticals is working with USFDA in resolving good manufacturing practices deviations at the facility and has taken corrective measures.

Analysts see this development has a negative for Sun Pharmaceuticals and see two implications – continued disruptions in maintaining supply commitments and impact of key pipeline approval for Sun Pharmaceuticals.

US FDA had made adverse observations in their audit of Halol plant last year and the company's sales last fiscal were impacted due to it. Elepsia XR is a novel extended release formulation of Levetiracetam tablets. Levetiracetam is an anti-epileptic drug indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, September 26 2015. 22:35 IST
RECOMMENDED FOR YOU
.